Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year survival below 30% ...

Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year ...

ETHealthworld.com brings latest quality of life news, views and updates from all top sources for the Indian Health industry.

Merck is picking up a big new piece for its cancer drug pipeline with a $6.7 billion deal to acquire Terns Pharmaceuticals, a company whose lead program could rival a blockbuster product from Novartis ...

Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML “The acquisition of Terns ...

RAHWAY, N.J., & FOSTER CITY, Calif.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN), a ...

SLS and TERN are advancing leukemia therapies, with TERN-701 targeting CML and GPS positioned as a Phase 3 maintenance immunotherapy in AML. ・Sellas is approaching a Phase 3 Regal survival readout, a ...

Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor c urrently in Phase 1/2 development for certain patients with CML Merck to hold investor call ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that the companies ...

JACKSON COUNTY, Colorado — The female wolf of the mating pair for the King Mountain pack has died, bringing total fatalities to 14 out of the 25 animals reintroduced in Colorado. The wolf, identified ...

Good news is on the horizon for Idaho’s deer and elk herds — and a mild winter deserves most of the credit. Statewide winter survival for mule deer fawns and elk calves has come in well above average ...